HemoGenyx Pharmaceuticals (LON:HEMO)

HemoGenyx Pharmaceuticals (LON:HEMO)


Share Price
2.17 p
Change
0.02 (0.93 %)
Market Cap
£7.82 m
Proactive Investors - Run By Investors For Investors

HemoGenyx Pharmaceuticals

HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility ("HemoGenyx").

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risk of...

EPIC: HEMO
Market: LSE:HEMO
52-week High/Low: 6.80p / 2.00p
Sector: Nonequity Investment Instruments
Market Cap: 7.82M
Website: www.hemogenyx.com
col 3
col 4
col 5
col 6

Big picture - Why invest in HemoGenyx Pharmaceuticals


HemoGenyx Pharmaceuticals Snapshot

Our passionate mission

We believe that we can transform patients' lives by delivering breakthrough therapies.

We also believe that good business means healthy people and a better world.

 

Develop - To develop new therapies that are based on breakthrough science

Hope - To bring hope to patients with serious or life threatening diseases

Treat - To treat life threatening diseases, bringing soecietal benefit

Value - To realise unique treatment opportunities for patients and value for investors

How it works

BM/HSC transplants includes a number of procedures whereby the BM/HSC of a patient are depleted and then replaced with hematopoietic stem/progenitor cells (HSPC) derived from the patient him/herself (Autologous HSCT) or from a donor (Allogeneic HSCT). Every BM/HSC transplant can be subdivided into three major stages. HemoGenyx's technologies target the first two stages where the greatest risks and limitations are, as shown below. Hemogenyx's technologies are complementary, but can also be used as stand alone products in line with traditional methods.

 

 

Hu-Phec

A Special Class of Cancer Free Cells For Hematopoetic/Bone Marrow Transplantation

HemoGenyx utilizes postnatal human hemogenic endothelial cells (Hu-PHEC cells), discovered by HemoGenyx Co-Founder Dr. Vladislav Sandler, to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers with superior results.

Hu-PHEC-based technology presents a number of important advantages compared to other existing and developing technologies. Most of these advantages are rooted in the fact that Hu-PHEC are a naturally occurring cell type found in adult and postnatal mammalian tissues. They can easily be isolated and do not require "heavy" manipulation before use. Hu-PHEC are “healthy” because they do not accumulate blood cancer-related mutations and/or chromosomal rearrangements, making them a perfect candidate for autologous (patient-specific) BM/HSC transplantations. In addition, Hu-PHEC can be propagated in vitro, allowing the introduction of therapeutic genes and gene modifications and making them a prime candidate for curative gene therapy applications.

HemoGenyx is developing Hu-PHEC technology based on cells isolated from two different sources:

Hu-PHEC isolated from umbilical cord and placenta:

Cord blood is extracted from the vessels of the umbilical cord and placenta of a donor using standard methods. To isolate endothelial cells emptied blood vessels of the tissues are treated using a proprietary method developed by HemoGenyx.

To isolate Hu-PHEC, endothelial cells are sorted using fluorescent activated cell sorting (FACS) using proprietary FDA certified reagents developed by HemoGenyx utilizing proprietary methods (patent pending; PCT Patent Application No. PCT/US2014/065469). Isolated Hu-PHEC are stored for further use in conjunction with standard cord blood cells for further use in transplantation. When needed, both Hu-PHEC and cord blood cells obtained from the same donor are used for hematopoietic transplantation per existing and widely practiced transplantation protocols.

Hu-PHEC isolated from the liver biopsy of a patient:

A liver biopsy is obtained from a patient per existing and widely practiced protocols. Endothelial cells are isolated from a liver biopsy of a patient using a proprietary method developed by HemoGenyx.

To isolate Hu-PHEC, endothelial cells are sorted using fluorescent activated cell sorting (FACS) using proprietary FDA certified reagents developed by HemoGenyx utilizing proprietary methods (patent pending; PCT Patent Application No. PCT/US2014/065469). Isolated Hu-PHEC are stored for further use in transplantation. When needed, liver Hu-PHEC are activated and intravenously transplanted to the patient they were obtained from.

 

 

CDX Antibodies

CDX Bi-specific Antibodies for Patient Conditioning

In order to obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, HemoGenyx developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies[1]. CDX antibodies belong to a class of bi-specific antibodies that redirect patients’ own immune cells to eliminate HSC. In addition, CDX antibodies show promise in efficiently eliminating malignant cells belonging to a subset of leukemia. In sum, CDX antibodies have the potential to both eliminate malignant leukemic cells and increase the efficiency of conditioning while diminishing the side effects that accompany traditional methods of patient conditioning.

Sir Marc Feldmann

Sir Marc Feldmann AC FAA FRS FRCP FRCPath FMedSci

CHAIRMAN
Person Details Link
Dr Vladislav

Dr Vladislav Sandler Ph.D.

CHIEF EXECUTIVE OFFICER AND CO-FOUNDER
Person Details Link
Dr Robin

Dr Robin Campbell

NON-EXECUTIVE DIRECTOR
Person Details Link
Lawrence

Lawrence Pemble

CHIEF OPERATING OFFICER
Person Details Link
Alexis M.

Alexis M. Sandler

NON-EXECUTIVE DIRECTOR AND CO-FOUNDER
Person Details Link
Peter

Peter Redmond

NON-EXECUTIVE DIRECTOR

 

Shares Issued

As at 5 October 2017, the number of shares in issue was 356,042,854.

Significant Shareholders

    On the date of Admission
Shareholder Number Ordinary 
Shares %
Flascherberg Capital Anstalt 27,996,487 7.86
Craig Auringer 31,407,913 8.82
Ron Valk 17,131,193 4.81
Plum Capital 11,692,863 3.28
43 North LLC 11,371,429 3.19
 

 

UK HEADQUARTERS

5 Fleet Place, London, EC4M 7RD, United Kingdom
[email protected]

RESEARCH FACILITY

760 Parkside Ave. Ste. 212 Brooklyn, NY 11226, US
[email protected]

MEDIA & INVESTOR RELATIONS

Walbrook PR Ltd. 4 Lombard St, London EC3V 9HD, United Kingdom
+44 (0)20 7933 8780

[email protected]

REGISTERED OFFICE

5 Fleet Place
London
EC4M 7RD

JOINT BROKER

Optiva Securities Limited
2 Mill Street
Mayfair
London
W1S 2AT

JOINT BROKER

Shard Capital Partners LLP
23rd Floor
20 Fenchurch Street
London
EC3M 3BY

RULE 3 ADVISER AND FINANCIAL ADVISER

Peterhouse Corporate Finance Limited
3rd Floor
New Liverpool House
15 Eldon Street
London
EC2M 7LD

AUDITORS AND REPORTING ACCOUNTANTS

PKF Littlejohn LLP
Westferry Circus
Canary Wharf
London
E14 4HD

REGISTRAR

Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol
BS13 8AE

LEGAL ADVISERS TO THE COMPANY AS TO ENGLISH LAW

Charles Russell Speechlys LLP
5 Fleet Place
London
EC4M 7RD

LEGAL ADVISERS TO THE COMPANY AS TO US LAW

Rubin & Rudman LLP
50 Rowes Wharf
Boston
Massachusetts 0211

FINANCIAL PR AND INVESTOR RELATIONS

Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD

Tel: 020 7933 8780
Email: [email protected]

Columns Including HEMO

VIEW ALL

Market Reports Including HEMO

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use